carvedilol has been researched along with Acute Disease in 14 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 9.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 7.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "This study was therefore designed to examine the effects of carvedilol on the transcriptional factor CREB in a murine model of acute viral myocarditis." | 7.79 | Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis. ( Li-Sha, G; Na-Dan, Z; Teng, Z; Yi-He, C; Yue-Chun, L, 2013) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 7.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "To compare the effects of cilazapril, carvedilol and their combination in preventing left ventricular remodelling (LVRM) after acute myocardial infarction (AMI) in rats." | 7.71 | Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats. ( Chen, J; Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y; Zhou, Y, 2002) |
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 5.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 3.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "This study was therefore designed to examine the effects of carvedilol on the transcriptional factor CREB in a murine model of acute viral myocarditis." | 3.79 | Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis. ( Li-Sha, G; Na-Dan, Z; Teng, Z; Yi-He, C; Yue-Chun, L, 2013) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 3.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "To compare the effects of cilazapril, carvedilol and their combination in preventing left ventricular remodelling (LVRM) after acute myocardial infarction (AMI) in rats." | 3.71 | Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats. ( Chen, J; Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y; Zhou, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Sessa, M | 1 |
| Rasmussen, DB | 1 |
| Jensen, MT | 1 |
| Kragholm, K | 1 |
| Torp-Pedersen, C | 1 |
| Andersen, M | 1 |
| Skrzypiec-Spring, M | 1 |
| Haczkiewicz, K | 1 |
| Sapa, A | 1 |
| Piasecki, T | 1 |
| Kwiatkowska, J | 1 |
| Ceremuga, I | 1 |
| Wozniak, M | 1 |
| Biczysko, W | 1 |
| Kobierzycki, C | 1 |
| Dziegiel, P | 1 |
| Podhorska-Okolow, M | 1 |
| Szelag, A | 1 |
| Horta, AL | 1 |
| Figueiredo, VP | 1 |
| Leite, ALJ | 1 |
| Costa, GP | 1 |
| Menezes, APJ | 1 |
| Ramos, CO | 1 |
| Pedrosa, TCF | 1 |
| Bezerra, FS | 1 |
| Vieira, PMA | 1 |
| Talvani, A | 1 |
| Li-Sha, G | 2 |
| Yi-He, C | 1 |
| Na-Dan, Z | 1 |
| Teng, Z | 1 |
| Yue-Chun, L | 2 |
| Lobo-Vielma, L | 1 |
| Colmenarez-Mendoza, H | 1 |
| Donis, JH | 1 |
| Sanchez, F | 1 |
| Perez, A | 1 |
| Villarroel, V | 1 |
| Dávila, DF | 1 |
| Pergola, G | 1 |
| Cascone, A | 1 |
| Russo, M | 1 |
| Yuan, Z | 1 |
| Shioji, K | 1 |
| Kihara, Y | 1 |
| Takenaka, H | 1 |
| Onozawa, Y | 1 |
| Kishimoto, C | 1 |
| Finsterer, S | 1 |
| Nentwich, Ch | 1 |
| Silber, S | 1 |
| Singh, TP | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Goch, JH | 1 |
| Chizyński, K | 1 |
| Jiang-Hua, R | 1 |
| Peng-Lin, Y | 1 |
| Jia-Feng, L | 1 |
| Ji-Fei, T | 1 |
| Peng, C | 1 |
| Zhan-Qiu, Y | 1 |
| O'Sullivan, JJ | 1 |
| Roche, SL | 1 |
| Crossland, DS | 1 |
| Chaudhari, MP | 1 |
| Kirk, RC | 1 |
| Asif, H | 1 |
| Brunner, M | 1 |
| Faber, TS | 1 |
| Greve, B | 1 |
| Keck, A | 1 |
| Schnabel, P | 1 |
| Jeron, A | 1 |
| Meinertz, T | 1 |
| Just, H | 1 |
| Zehender, M | 1 |
| Yang, Y | 1 |
| Tang, Y | 1 |
| Ruan, Y | 1 |
| Li, Y | 1 |
| Zhou, Y | 1 |
| Gao, R | 1 |
| Chen, J | 1 |
| Chen, Z | 1 |
1 review available for carvedilol and Acute Disease
| Article | Year |
|---|---|
[The value of BNP determination in general practice].
Topics: Acute Disease; Antihypertensive Agents; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic | 2004 |
2 trials available for carvedilol and Acute Disease
| Article | Year |
|---|---|
[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Bisoprolol; | 2006 |
Usefulness of carvedilol in unstable angina pectoris.
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; An | 2000 |
11 other studies available for carvedilol and Acute Disease
| Article | Year |
|---|---|
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carbazoles; Carvedilol; Di | 2018 |
The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Carvedilol; Catalase; Chagas Disease; Cytokines | 2018 |
Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coxsackievirus Infectio | 2013 |
Acutely decompensated systolic heart failure: effects of frequent doses of furosemide vs a single dose plus carvedilol on clinical status, neurohormonal activation and ventricular arrhythmias.
Topics: Acute Disease; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Administration S | 2010 |
Acute pericarditis and myocarditis by Toxoplasma gondii in an immunocompetent young man: a case report.
Topics: Acute Disease; Adult; Aluminum Hydroxide; Antibodies, Protozoan; Carbazoles; Carvedilol; Chest Pain; | 2010 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Autoimm | 2004 |
Clinical trials of newly developed anti-cancer agents in children with acute leukemia.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Carbazoles; Ca | 2006 |
Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Carbazo | 2008 |
Recovery of heart function in children with acute severe heart failure.
Topics: Acute Disease; Captopril; Carbazoles; Cardiotonic Agents; Carvedilol; Child; Child, Preschool; Datab | 2008 |
Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carba | 2002 |